Evidence map›Paper›PMID 19643141›Full record

ArticleJournal of virological methods2009

Simultaneous assessment of CD4 and MHC-I downregulation by Nef primary isolates in the context of infection.

Ayub Ali, Susan Realegeno, Otto O Yang, Martha J Lewis

Abstract read
In one paragraph

Article in Journal of virological methods, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ayub AliDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Susan Realegeno
Otto O Yang
Martha J Lewis
University of California, Los Angeles · USBlack AIDS Institute · US

Funding

MARC U*STAR Program at the University of California, Los AngelesT34GM008563 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCEVOY, MEGAN M, POE, GINA R · 1996 to 2023
$9.7M
Immune Pressure on HIV-1 Nef by Cytotoxic T LymphocytesR01AI051970 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YANG, OTTO O · 2002 to 2011
$4.1M
Factors/HIV-1 Nef's Ability to Direct Immune EvasionK08AI068449 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LEWIS, MARTHA J · 2006 to 2009
$257k
NIAID NIH HHS K08 AI068449NIAID NIH HHS R01 AI051970
6 · The paper itself

Abstract

The HIV-1 Nef protein plays a key role in pathogenesis, as demonstrated by strong selective pressure to maintain its open reading frame, and disease attenuation when it is deleted. Among myriad cellular effects attributed to Nef, downregulation of cell surface CD4 and major histocompatibility complex class I (MHC-I) proteins are the best documented. However, few data regarding primary isolate Nef functions are available, and most studies have been performed using transient transfections to express Nef driven by a non-physiologic promoter. A novel assay system to measure simultaneously the downregulation of CD4 and MHC-I by primary HIV-1 nef in a more physiologic viral genomic context is presented. Examination of plasma nef mixtures allowed comprehensive profiling of these Nef functions within the quasispecies in vivo. Subsets within the circulating nef population were observed that are either fully functional or non-functional. These data demonstrated that this assay system allows rapid characterization of bulk and clonal Nef functional profiles that can be used in pathogenesis studies to define further its important role in pathogenesis.

Indexed as

CD4 AntigensCell LineDown-Regulationenv Gene Products, Human Immunodeficiency VirusHistocompatibility Antigens Class IHIV-1HIV InfectionsHIV Long Terminal RepeatHost-Pathogen InteractionsHuman Immunodeficiency Virus ProteinsHumansnef Gene Products, Human Immunodeficiency VirusPromoter Regions, GeneticRecombinant Fusion ProteinsViral Regulatory and Accessory ProteinsVirologyCD4 Antigensenv Gene Products, Human Immunodeficiency VirusHistocompatibility Antigens Class IHuman Immunodeficiency Virus Proteinsnef Gene Products, Human Immunodeficiency Virusnef protein, Human immunodeficiency virus 1Recombinant Fusion ProteinsViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1

Identifiers

PMID19643141
PMCPMC2758048
OpenAlexW1992570503

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.